Peter Horby

Sir Peter William Horby is a British physician, epidemiologist, Moh Family Foundation Professor of Emerging Infections and Global Health, and Director of the Pandemic Sciences Institute at the University of Oxford. He is the founder, and former director of the Oxford University Clinical Research Unit in Hanoi, Vietnam which was founded in 2006. In 2014, Horby established the Epidemic Research Group Oxford (ERGO). ERGO incorporates a number of international projects such as the European Commission funded PREPARE, the African coaLition for Epidemic Research, Response and Training (ALERRT), and the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC). Since 2016, Horby has been chair and executive director of ISARIC.

Sir

Peter Horby
Born
Peter William Horby
Alma materUniversity College London (MBBS)
London School of Hygiene and Tropical Medicine (PhD)
Scientific career
InstitutionsUniversity of Oxford
ThesisAvian, inter-pandemic, and pandemic influenza in Vietnam
Doctoral advisorNeal Alexander
Websitewww.ndm.ox.ac.uk/team/peter-horby

Horby specialises in emerging and epidemic infectious diseases. He is the co-chief investigator of the RECOVERY Trial into drugs for COVID-19 (the largest clinical trial of COVID-19 in the world) alongside Martin Landray.[1][2][3] In June 2020, he gave a statement at 10 Downing Street alongside the Prime Minister and Chief Scientific Adviser announcing the first positive trial results of the first life-saving COVID-19 drug, Dexamethasone.[4][5] He is the primary author on the published preliminary report.[6]

From 2020 to 2022, Horby was one of the attendees of the Scientific Advisory Group for Emergencies (SAGE) [7] He is the chair of the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG).[8][7]

He was knighted in the 2021 Birthday Honours for services to medical research.[9]

References
  1. "ISRCTN - ISRCTN50189673: A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus)". www.isrctn.com. Retrieved 6 September 2020.
  2. "Large-scale trial for coronavirus drugs launches in UK". Clinical Trials Arena. 6 April 2020. Retrieved 7 September 2020.
  3. "Managing clinical trials during the pandemic — Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences". www.ndorms.ox.ac.uk. Retrieved 7 September 2020.
  4. "Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 | University of Oxford". www.ox.ac.uk. Retrieved 6 September 2020.
  5. "Prime Minister's statement on coronavirus (COVID-19): 16 June 2020". GOV.UK. 16 June 2020. Retrieved 6 September 2020.
  6. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. (July 2020). "Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report". The New England Journal of Medicine. 384 (8): 693–704. doi:10.1056/NEJMoa2021436. PMC 7383595. PMID 32678530.
  7. Sample, Ian (24 April 2020). "Who's who on secret scientific group advising UK government?". The Guardian. Retrieved 24 April 2020.
  8. "New and Emerging Respiratory Virus Threats Advisory Group". gov.uk. Retrieved 24 April 2020.
  9. "No. 63377". The London Gazette (Supplement). 12 June 2021. p. B2.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.